The knowns and unknowns of teprotumumab for thyroid eye disease
- PMID: 33865499
- DOI: 10.1016/S2213-8587(21)00076-0
The knowns and unknowns of teprotumumab for thyroid eye disease
Conflict of interest statement
TB reports personal fees from Berlin-Chemie/Menarini and personal fees from Ipsen, Merck, and Novartis. SHP reports personal fees from Quidel, Berlin-Chemie, and Sanofi; and personal fees and other funding from Apitope.
Comment on
-
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372. doi: 10.1016/S2213-8587(21)00056-5. Epub 2021 Apr 15. Lancet Diabetes Endocrinol. 2021. PMID: 33865501 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
